Cargando…
Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer
The epidermal growth factor receptor (EGFR) inhibitor cetuximab is the only FDA-approved oncogene-targeting therapy for head and neck squamous cell carcinoma (HNSCC). Despite variable treatment response, no biomarkers exist to stratify patients for cetuximab therapy in HNSCC. Here, we applied unbias...
Autores principales: | Bouhaddou, Mehdi, Lee, Rex H., Li, Hua, Bhola, Neil E., O’Keefe, Rachel A., Naser, Mohammad, Zhu, Tian Ran, Nwachuku, Kelechi, Duvvuri, Umamaheswar, Olshen, Adam B., Roy, Ritu, Hechmer, Aaron, Bolen, Jennifer, Keysar, Stephen B., Jimeno, Antonio, Mills, Gordon B., Vandenberg, Scott, Swaney, Danielle L., Johnson, Daniel E., Krogan, Nevan J., Grandis, Jennifer R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564908/ https://www.ncbi.nlm.nih.gov/pubmed/34546978 http://dx.doi.org/10.1172/jci.insight.151982 |
Ejemplares similares
-
Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance
por: O’Keefe, Rachel A., et al.
Publicado: (2020) -
Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts
por: Lee, Rex H., et al.
Publicado: (2023) -
Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020) -
Current proteomics methods applicable to dissecting the DNA damage response
por: Muralidharan, Monita, et al.
Publicado: (2023) -
Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)